{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:44:10Z","timestamp":1767894250038,"version":"3.49.0"},"reference-count":36,"publisher":"Hindawi Limited","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":822,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast J"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1111\/tbj.12152","type":"journal-article","created":{"date-parts":[[2013,6,26]],"date-time":"2013-06-26T09:46:35Z","timestamp":1372239995000},"page":"n\/a-n\/a","source":"Crossref","is-referenced-by-count":8,"title":["Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study"],"prefix":"10.1155","author":[{"given":"Adam M.","family":"Brufsky","sequence":"first","affiliation":[{"name":"Hematology\/Oncology; University of Pittsburgh Medical Center; Pittsburgh; Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Sereika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aju","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine; University of Pittsburgh Medical Center; Pittsburgh; Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onishi","family":"Tomifumi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine; University of Pittsburgh Medical Center; Pittsburgh; Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikramjit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine; University of Pittsburgh Medical Center; Pittsburgh; Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"Graduate School of Public Health; University of Pittsburgh; Pittsburgh; Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,6,26]]},"reference":[{"key":"10.1111\/tbj.12152-BIB0001|tbj12152-cit-0001","unstructured":"American Cancer Society Breast Cancer Facts & Figures 2009-2010 Atlanta, GA American Cancer Society Inc 2009 http:\/\/www.cancer.org\/acs\/groups\/content\/@nho\/documents\/document\/f861009final90809pdf.pdf"},{"key":"10.1111\/tbj.12152-BIB0002|tbj12152-cit-0002","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2009.04.022","article-title":"Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?","volume":"45","author":"Coleman","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1111\/tbj.12152-BIB0003|tbj12152-cit-0003","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients' quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1111\/tbj.12152-BIB0004|tbj12152-cit-0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.327.7413.469","article-title":"Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer","volume":"327","author":"Ross","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/tbj.12152-BIB0005|tbj12152-cit-0005","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1111\/tbj.12152-BIB0006|tbj12152-cit-0006","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/tbj.12152-BIB0007|tbj12152-cit-0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.330.7494.769","article-title":"Recent developments in bisphosphonates for patients with metastatic breast cancer","volume":"330","author":"Gainford","year":"2005","journal-title":"BMJ"},{"key":"10.1111\/tbj.12152-BIB0008|tbj12152-cit-0008","unstructured":"Xgeva (denosumab) Thousand Oaks, CA Amgen Inc 2010"},{"key":"10.1111\/tbj.12152-BIB0009|tbj12152-cit-0009","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/tbj.12152-BIB0010|tbj12152-cit-0010","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0011|tbj12152-cit-0011","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0012|tbj12152-cit-0012","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0013|tbj12152-cit-0013","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1634\/theoncologist.2008-0227","article-title":"High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid","volume":"14","author":"Zuradelli","year":"2009","journal-title":"Oncologist"},{"key":"10.1111\/tbj.12152-BIB0014|tbj12152-cit-0014","first-page":"524","article-title":"Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model","volume":"4","author":"McDermott","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1111\/tbj.12152-BIB0015|tbj12152-cit-0015","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0016|tbj12152-cit-0016","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1200\/JCO.2001.19.14.3434","article-title":"Safety and efficacy of bisphosphonates beyond 24\u00a0months in cancer patients","volume":"19","author":"Ali","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0017|tbj12152-cit-0017","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0018|tbj12152-cit-0018","unstructured":"Zometa (zoledronic acid) [package insert] East Hanover, NJ Novartis Pharmaceuticals Corporation 2011"},{"key":"10.1111\/tbj.12152-BIB0019|tbj12152-cit-0019","unstructured":"Aredia [prescribing information] East Hanover, NJ Novartis Pharmaceuticals Corporation 2008"},{"key":"10.1111\/tbj.12152-BIB0020|tbj12152-cit-0020","unstructured":"Department of Health and Human Services Approval letter for application number NDA 21-223\/S-009 & S-010 Rockville, MD Food and Drug Administration http:\/\/theoncologist.alphamedpress.org\/site\/misc\/Zometa_FDA_Ltr_David_Orloff.pdf"},{"key":"10.1111\/tbj.12152-BIB0021|tbj12152-cit-0021","unstructured":"Department of Health and Human Services Approval letter for application number NDA 20-036\/S-034 Rockville, MD Food and Drug Administration http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2007\/020036s034ltr.pdf"},{"key":"10.1111\/tbj.12152-BIB0022|tbj12152-cit-0022","doi-asserted-by":"crossref","first-page":"864","DOI":"10.14219\/jada.archive.2009.0280","article-title":"Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review","volume":"140","author":"Almazrooa","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"10.1111\/tbj.12152-BIB0023|tbj12152-cit-0023","first-page":"801","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"35","author":"Sambrook","year":"2006","journal-title":"Aust Fam Physician"},{"key":"10.1111\/tbj.12152-BIB0024|tbj12152-cit-0024","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1111\/tbj.12152-BIB0025|tbj12152-cit-0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"10.1111\/tbj.12152-BIB0026|tbj12152-cit-0026","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0027|tbj12152-cit-0027","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1111\/tbj.12152-BIB0028|tbj12152-cit-0028","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1111\/tbj.12152-BIB0029|tbj12152-cit-0029","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/tbj.12152-BIB0030|tbj12152-cit-0030","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/tbj.12152-BIB0031|tbj12152-cit-0031","unstructured":"Morgan G MRC Myeloma IX Trial-Characterising the biologic and temporal basis of efficacy of long-term bisphosphonate treatment in patients with multiple myeloma [oral presentation]"},{"key":"10.1111\/tbj.12152-BIB0032|tbj12152-cit-0032","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12152-BIB0033|tbj12152-cit-0033","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1111\/tbj.12152-BIB0034|tbj12152-cit-0034","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1111\/tbj.12152-BIB0035|tbj12152-cit-0035","doi-asserted-by":"crossref","first-page":"732s","DOI":"10.1200\/jco.2008.26.15_suppl.20597","article-title":"Baseline characteristics, prior bisphosphonate (BPH) therapy (Rx), and clinical parameters of patients in LOTUZ, a prospective pharmacoepidemiological study of long-term zoledronic acid (ZOL) treatment (>2\u00a0years) in patients (pts) with solid and hematologic malignancies","volume":"26","author":"Wildiers","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/tbj.12152-BIB0036|tbj12152-cit-0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat Rev"}],"container-title":["The Breast Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftbj.12152","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tbj.12152\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:26:20Z","timestamp":1643351180000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tbj.12152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1111\/tbj.12152","relation":{},"ISSN":["1075-122X"],"issn-type":[{"value":"1075-122X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}